Clinical Trial Update: Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the effect of time-of-day immunochemotherapy on progression-free survival in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED